Skip to main content
SpringerLink
Log in

Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets

  • Chapter
  • First Online:
Atherosclerosis, Hypertension and Diabetes

Part of the book series: Progress in Experimental Cardiology ((PREC,volume 8))

  • 181 Accesses

Abstract

Platelets, when activated contribute to the development of atherosclerosis through releasing growth promoting, vasoconstricting, and pro-aggregating substances. The end product is atherosclerotic plaque formation and thrombus formation, an important cause of fatal and morbid cardiac events. HMG CoA reductase inhibitors have been shown to reduce fatal and morbid cardiovascular events significantly. The objective of the present study was to determine whether treatment with the HMG CoA reductase inhibitor simvastatin would reduce the increased state of platelet activation in hyperlipidemic patients and thereby con-tribute to the beneficial effect of HMG CoA reductase inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kannel WB, Castelli WP, Gordon T, McNamara PM. 1971. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Int Med 74:1–12.

    PubMed  CAS  Google Scholar 

  2. Ross R. 1993. The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature 362:80–809.

    Article  Google Scholar 

  3. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. 1990. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86:228–234.

    Article  PubMed  CAS  Google Scholar 

  4. Celemajer DS, Sorensen KE, Gooch VM, et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115.

    Article  Google Scholar 

  5. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. 1993. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation 88(part 1):2139–2148.

    Article  PubMed  CAS  Google Scholar 

  6. Treasure CB, Klein JL, Weintraub WS, et al. 1995. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332:481–487.

    Article  PubMed  CAS  Google Scholar 

  7. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. 1995. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488–493.

    Article  PubMed  CAS  Google Scholar 

  8. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G. 2001. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normo-cholesterolemic men. Am J Cardiol 88:1306–1307.

    Article  PubMed  CAS  Google Scholar 

  9. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. 1994. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89:2519–2524.

    Article  PubMed  CAS  Google Scholar 

  10. Nievelstein PFEM, de Groot PG. 1988. Interaction of blood platelets with the vessel wall. Haemostasis 18:342–359.

    PubMed  CAS  Google Scholar 

  11. Ross R, Glomset J, Kariya B, Harker L. 1974. A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 71:1207–1210.

    Article  PubMed  CAS  Google Scholar 

  12. Vanhoutte PM. 1989. Endothelium, platelets, and vasospasm. In: P. Meyer and P. March, Blood cells and arteries in hypertension and atherosclerosis, page 1–14. Raven Press, New York.

    Google Scholar 

  13. Carvalho AC, Colman RW, Lees RS. 1974. Platelet function in hperlipoproteinemia. N Engl J Med 290:434–438.

    Article  PubMed  CAS  Google Scholar 

  14. Brook G, Winterstein G, Aviram M. 1983. Platelet function and lipoprotein levels after plasma exchange in patients with familial hypercholesterolemia. Cli Sci 64:637–642.

    CAS  Google Scholar 

  15. Hassall DG, Forrest LA, Bruckdorfer R, Marenah CB, Turner P, Cortese C, Miller E, Lewis B. 1983. Influence of plasma lipoproteins in a normal male population. Arteriosclerosis 3:332–338.

    Article  PubMed  CAS  Google Scholar 

  16. Knorr M, Locher R, Vogt E, Vetter W, Block LH, Ferracin F, Levkovits H, Pletscher A. 1988. Rapid activation of human platelets by low concentrations of low-density lipoprotein via phos-phatidyl inositol cycle. Eur J Biochem 172:753–759.

    Article  PubMed  CAS  Google Scholar 

  17. Bochkov VN, Rozhkova TA, Matchin YuG, Lyakishev AA, Bochkova NA, Borisova YuL, Kukharchuk VV, Tchachuk VA. 1991. LDL and agonist-induced Ca2+ mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. Thromb Res 61:403–409.

    Article  PubMed  CAS  Google Scholar 

  18. Aviram M, Brook JG. 1987. Platelet activation by plasma proteins. Progr Cardiovasc Dis 30: 61–72.

    Article  CAS  Google Scholar 

  19. Curtiss LK, Plow EF. 1984. Interaction of plasma lipoprotein with human platelets. Blood 64: 365–374.

    PubMed  CAS  Google Scholar 

  20. Kuo PT. 1981. Lipoproteins, platelets, and prostaglandins in atherosclerosis. Amer Heart J 102: 949–953.

    Article  PubMed  CAS  Google Scholar 

  21. Katzman PL, Bose R, Henry S, McLean DL, Walker S, Fyfe C, Perry Y, Mymin D, Bolli P. 1994. Serum lipid profile determines platelet reactivity to native and modified LDL¡ªcholesterol in humans. Thrombosis Haemostasis 71:627–632.

    CAS  Google Scholar 

  22. Ardlie NG, Selley ML, Simons LA. 1989. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 76:117–124.

    Article  PubMed  CAS  Google Scholar 

  23. Meraji S, Moore CE, Skinner VO, Bruckdorfer KR. 1992. The importance of oxidation or glycosylation of low-density lipoproteins in relation to platelet activation. Platelets 3:155–162.

    Article  Google Scholar 

  24. Koller E, Koller F, Doleschel W. 1982. Specific binding sites on human blood platelets for plasma lipo-proteins. Hoppe-Seyler Z Physiol Chem 363:395–405.

    Article  PubMed  CAS  Google Scholar 

  25. Katzman PL, Bose R, Walker S, Perry Y, Bolli P. 1991. Temperature-dependence of LDL binding and activation of human platelets. Thromb Res 64:503–508.

    Article  PubMed  CAS  Google Scholar 

  26. Lapetina EG. 1989. The biochemical messengers of activated platelets. In: P. Meyer and P. Marche, Blood cells and arteries in hypertension and atherosclerosis, pages 47–57. Raven Press, New York.

    Google Scholar 

  27. Friedewald WT, Levy RI, Frederickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18:499–502.

    PubMed  CAS  Google Scholar 

  28. Standley PR, Gangasani S, Prakash R, Zemel MB, Sowers JR. 1991. Human platelet calcium measurements: Methodological considerations and comparisons with calcium mobilization in vascu-lar smooth muscle cells. Am J Hypertension 4:546–549.

    CAS  Google Scholar 

  29. Erne P, Bolli P, Burgisser E, Buhler FR. 1984. Correlation of platelet calcium with blood pressure; effect of antihypertensive therapy. N Engl J Med 310:1084–1088.

    Article  PubMed  CAS  Google Scholar 

  30. Grynkiewicz G, Poenie M, Tsien RY. 1985. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440–3450.

    PubMed  CAS  Google Scholar 

  31. Oshima T, Young EW, Bukosi RD, McCarron DA. 1990. Abnormal calcium handling by platelets of spontaneously hypertensive rats. Hypertension 5:606–611.

    Article  Google Scholar 

  32. Livshits G, Weibort J, Meshulam N, Brunner D. 1989. Multivariate analysis of the twenty-year follow-up of the Donolo-Tel Aviv prospective coronary artery disease study and the usefulness of high density lipoprotein cholesterol percentage. Am J Cardiol 63:676–681.

    Article  PubMed  CAS  Google Scholar 

  33. Hamiwka L. 1994. Platelet derived growth factor release by human platelets in vitro: effects of thrombin, lipids and cyclosporine. B Med Sci Thesis.

    Google Scholar 

  34. Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan V. 1994. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 43:11–17.

    Article  PubMed  CAS  Google Scholar 

  35. Le Quan Sang KH, Levenson J, Megnicu JL, Simon A, Devyuck MA. 1995. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia; Effects of pravastatin. Arterioscler Thromb Vasc Biol 15:759–764.

    Article  Google Scholar 

  36. Lacoste L, Lam JYT. 1995. Hyperlipidemia and coronary artery disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92:3172–3177.

    Article  PubMed  CAS  Google Scholar 

  37. Rosenson RS, Tangney CC. 1998. Antiatherothrombic properties of statins. Implications of cardiovascular event reduction. JAMA 279:1643–1650.

    Article  PubMed  CAS  Google Scholar 

  38. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389.

    Google Scholar 

  39. The Pravastatin Multinational Study Group for Cardiac Risk Patients. 1993. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/liter plus two additional atherosclerotic risk factors. Am J Cardiol 72:1031–1037.

    Article  Google Scholar 

  40. Salonen R, Nyyssonen K, Porkkala E, et al. 1995. Kuopio Atherosclerosis Prevention Study (KAPS): A population based primary primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92:1758–1764.

    Article  PubMed  Google Scholar 

  41. Shepherd J, Cobb SM, Ford I, et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1307.

    Article  Google Scholar 

  42. Lansky AJ, Desai K, Leon MB. 2002. Quantative coronary angiography in regression trials: A review of methodologic considerations, endpoint selection, and limitations. Am J Cardiol 89(Suppl):4B–9B.

    Article  PubMed  Google Scholar 

  43. The Heart Protection Study. 2001. Presented at the 74th Scientific Sessions of the American Heart Association, Anaheim, Ca, November 13.

    Google Scholar 

  44. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA 285:1711–1717.

    Article  PubMed  CAS  Google Scholar 

  45. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, Takeshita A. 2001. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 88:1291–1294.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Stephen Henry, Ratna Bose, Yvette Perry, Shaun Walker & David Mymin

  2. Department of Medicine, Central Hospital, Helsingborg, Sweden

    Per L. Katzman

  3. Niagara Clinical Teaching and Research Centre, St. Catharines, Canada

    Peter Bolli

Authors
  1. Stephen Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per L. Katzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ratna Bose
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yvette Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaun Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Mymin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Bolli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Stroke & Vascular Disease, St. Boniface General Hospital Research Centre, Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Grant N. Pierce PhD, FACC (Professor & Director) (Professor & Director)

  2. Department of Medicine, Jikei University School of Medicine, Tokyo, Japan

    Makoto Nagano MD, PhD (Professor Emeritus) (Professor Emeritus)

  3. Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Peter Zahradka PhD (Associate Professor) & Naranjan S. Dhalla PhD, MD (Hon), DSc (Hon) (Distinguished Professor and Director) (Associate Professor) &  (Distinguished Professor and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Henry, S. et al. (2003). Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets. In: Pierce, G.N., Nagano, M., Zahradka, P., Dhalla, N.S. (eds) Atherosclerosis, Hypertension and Diabetes. Progress in Experimental Cardiology, vol 8. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9232-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9232-1_9

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4850-4

  • Online ISBN: 978-1-4419-9232-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation